<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01341717</url>
  </required_header>
  <id_info>
    <org_study_id>JDC/SITA/021/2011</org_study_id>
    <nct_id>NCT01341717</nct_id>
  </id_info>
  <brief_title>Effects of Sitagliptin on Type 2 Diabetes Mellitus Patients on Treatment With Metformin and Insulin</brief_title>
  <official_title>Open-labelled, Randomized, Active-controlled, Parallel-arm, Single-center Study on Effect of Sitagliptin on T2DM Patients on Treatment With Metformin and Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jothydev's Diabetes and Research Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jothydev's Diabetes and Research Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the efficacy and safety of sitaglipin in the
      treatment of Type 2 diabetes mellitus (T2DM) patients with inadequate glycemic control using
      metformin and insulin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DPP-4 inhibitors enhance function of endogenous incretin that helps with glucose
      homoeostasis. DPP-4 inhibitors have been proved to promote glycemic control without
      increasing risk of hypoglycemia and weight gain. In addition, they may improve beta-cell
      function and do not have any known associations with overt cardiovascular or hepatic safety
      risks.

      Addition of sitagliptin to treatment of T2DM patients poorly controlled on insulin +/-
      metformin has been shown to reduce HbA1c while being generally well-tolerated.

      It could be clinically useful to add sitaglipin to treatment regimen of T2DM patients on
      stable therapy with insulin &amp; metformin. Apart from glycemic reduction, secondary effects
      like prevention of weight gain, reduction in insulin dose, improved cardiovascular risk
      profile, etc. may be expected from addition of sitagliptin to treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in HbA1c from baseline</measure>
    <time_frame>six months</time_frame>
    <description>To confirm the efficacy of metformin+ insulin+ sitagliptin in controlling glycemia with respect to change from baseline in HbA1c after 24 weeks of administration. This will be accomplished by comparing the difference in change from baseline in HbA1c after 24 weeks of administration, compared with metformin+insulin+glimepiride to a non-inferiority limit of 0.3% , and if non-inferiority is proven, to a superiority limit of 0%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in total daily dose (TDD) of insulin</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline in insulin TDD (30-day geometric mean) at Month 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episodes of hypoglycemia</measure>
    <time_frame>6 months</time_frame>
    <description>Hypoglycemia (Total, severe, nocturnal) (From Month 0 to Month 6), as assessed by questionnaire and supplemented by SMBG values, if available</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with HbA1c reduction</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients, who completed treatment , with HbA1c value &lt;6.5% &amp; ≤7.3% at end of study (Month 6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in weight and BMI</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in both HbA1c and TDD</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients achieving both HbA1c ≤6.5% AND reduction in TDD (total daily dose of insulin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin resistance and beta cell function</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline in c-peptide levels, homeostasis model assessments of β-cell function and insulin resistance (HOMA-β and HOMA-IR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipid profile from baseline</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">440</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Sitagliptin along with metformin and insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Glimepiride as an active comparator to Sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>100 mg once daily for 6 months</description>
    <arm_group_label>Sitagliptin along with metformin and insulin</arm_group_label>
    <arm_group_label>Glimepiride as an active comparator to Sitagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>1 mg/2 mg/3 mg once daily</description>
    <arm_group_label>Sitagliptin along with metformin and insulin</arm_group_label>
    <arm_group_label>Glimepiride as an active comparator to Sitagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>&gt;=1000 mg twice daily</description>
    <arm_group_label>Sitagliptin along with metformin and insulin</arm_group_label>
    <arm_group_label>Glimepiride as an active comparator to Sitagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>TDD &gt; 10 IU once/twice daily</description>
    <arm_group_label>Sitagliptin along with metformin and insulin</arm_group_label>
    <arm_group_label>Glimepiride as an active comparator to Sitagliptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  T2DM patients on metformin and biphasic or basal regimens of insulin

          -  HbA1c ≥7.3% to ≤8.5%

          -  Age: 25 to 60 yrs

          -  Insulin TDD &gt; 10 IU

        Exclusion Criteria:

          -  Use of acarbose, pioglitazone or short-acting insulin analogues at time of run-in
             phase

          -  History of type 1 diabetes mellitus

          -  Creatinine clearance ≤50 mL/min

          -  Chronic liver &amp; kidney diseases, SGOT/PT≥2.5x upper limit of normal, uncontrolled
             thyroid disorders , cardiac failure, hemochromatosis, autoimmune disorders,
             corticosteroid intake.

          -  BMI &gt;40 kg/m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jothydev Kesavadev, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jothydev's Diabetes and Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jothydev's Diabetes and Research Center</name>
      <address>
        <city>Thiruvananthapuram</city>
        <state>Kerala</state>
        <zip>695032</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001356/</url>
    <description>About Diabetes Mellitus</description>
  </link>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2011</study_first_submitted>
  <study_first_submitted_qc>April 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2011</study_first_posted>
  <last_update_submitted>May 29, 2014</last_update_submitted>
  <last_update_submitted_qc>May 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <keyword>Sitagliptin</keyword>
  <keyword>Insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

